Dr. Lawrence Joseph Planchard, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 2400 Hospital Dr, Suite 100, Bossier City, LA 71111 Phone: 318-212-7860 Fax: 318-212-7865 |
Dr. Thomas A. Planchard, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2400 Hospital Dr, Suite 100, Bossier City, LA 71111 Phone: 318-212-7860 Fax: 318-212-7865 |
Dr. Norman A. Zaffater Jr., M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2449 Hospital Dr Ste 460, Bossier City, LA 71111 Phone: 318-747-5838 Fax: 318-747-5827 |
Wally R Nawas, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2300 Hospital Drive, Suite 140, Bossier City, LA 71111 Phone: 318-746-2020 Fax: 318-741-3508 |
Yue Kong Au, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 2539 Viking Dr, Suite 103, Bossier City, LA 71111 Phone: 318-742-3399 Fax: 318-742-4499 |
News Archive
Threshold Pharmaceuticals, Inc. today announced that it has initiated a multi-center, randomized, controlled, crossover Phase 2 clinical trial of TH-302 in combination with gemcitabine in patients with first line pancreatic cancer. TH-302 is a proprietary tumor selective Hypoxia-Activated Prodrug that specifically targets tumor hypoxia.
New statistics released today by the American Society of Plastic Surgeons show that breast lift procedures are growing at twice the rate of breast implant surgeries. Since 2000, breast lifts have grown by 70 percent, outpacing implants two-to-one. Breast implants are still by far the most performed cosmetic surgery in women, but lifts are steadily gaining. In 2013, more than 90,000 breast lift procedures were performed by ASPS member surgeons.
Scientists have identified a protein that plays a key role in debilitating changes that occur in the heart after a heart attack, according to research reported in Circulation Research: Journal of the American Heart Association.
A new cancer vaccine could boost the positive effects of existing immunotherapy drugs, improving the success rate of treatments from 20% to 75% of cases, according to a new study by immunologists from the University of Konstanz.
Sysmex America, Inc., a leading medical diagnostic instrument manufacturer and information systems developer, today announced that its Sysmex XT-4000i™ Automated Hematology Analyzer has been cleared by the United States Food and Drug Administration (FDA).
› Verified 2 days ago